Receptor News and Research

RSS

Study shows distinctive mutation in rapidly emerging SARS-CoV-2 B.1.1.7 sublineage

In a new study currently available on the medRxiv* preprint server, US researchers report the detection of a specific sub-lineage of B.1.1.7 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant harboring a novel S:D178H mutation and elucidate its transmission and evolutionary patterns.

21 May 2021

Researchers define immune determinants of protection against SARS-CoV-2 in mice

Researchers in the United States have conducted a preclinical study defining the roles that different arms of the immune system play in fighting primary infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as reinfection and infection following SARS-CoV-2 vaccination.

21 May 2021

New peptides allow cannabis-derived drugs to fight pain in mice without side effects

An international team, led by researchers from Pompeu Fabra University (UPF) in Barcelona, Spain, David Andreu and Rafael Maldonado, has developed a peptides family that allows delta-9-tetrahydrocannabinol (THC), the main component of Cannabis sativa, to fight pain in mice without side effects.

20 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Researchers tested the vaccine candidate in mice with up to three doses and found it produces high levels of antibodies against both SARS-CoV-2 variants of concern and the original virus strain.

20 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

Study could serve as guidepost for developing new therapies for Alzheimer's disease

In a major breakthrough, researchers at Massachusetts General Hospital (MGH) have discovered how amyloid beta--the neurotoxin believed to be at the root of Alzheimer's disease (AD)--forms in axons and related structures that connect neurons in the brain, where it causes the most damage.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Researchers from the US recently assessed if severe COVID-19 is linked to procoagulant dysfunction of the endothelium and changes in the Tie2-angiopoietin axis. They assessed circulating endothelial markers in a study cohort of 98 patients with mild, moderate, or severe COVID-19. This study is published on the medRxiv* preprint server.

19 May 2021

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

19 May 2021

B.1.1.7 not associated with change in serial interval of COVID-19

With data obtained from the Virus Watch study in England and Wales, researchers found that the serial interval of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is broadly similar to estimates from previous studies and there is no evidence that the B.1.1.7 variant is associated with any change.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

Researchers at St Jude Children’s Research Hospital found that toll-like receptor 2 detects the SARS-CoV-2 envelope protein-producing inflammatory cytokines.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

DNAM-1 receptor could be used as new molecular target for treating autoimmune diseases

Autoimmune diseases occur when an individual's immune system fights their own body as if it was a foreign invader. However, in healthy people, these responses are prevented by a process known as immune tolerance

19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

Receptor News and Research

Study shows distinctive mutation in rapidly emerging SARS-CoV-2 B.1.1.7 sublineage

Researchers define immune determinants of protection against SARS-CoV-2 in mice

New peptides allow cannabis-derived drugs to fight pain in mice without side effects

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Are COVID-19-related complications in children explained by abnormal immune responses?

Study could serve as guidepost for developing new therapies for Alzheimer's disease

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Antithrombotic endothelial dysfunction is prevented by Tie2 activation in severe COVID-19

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

B.1.1.7 not associated with change in serial interval of COVID-19

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Spike antibodies after vaccination with Pfizer and Oxford vaccines

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

DNAM-1 receptor could be used as new molecular target for treating autoimmune diseases

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News